New developments in epilepsy drugs: eslicarbazepine's first imitation approved soon

A few days ago, Yangtze River Pharmaceutical Group Beijing Haiyan Pharmaceutical Co.

Eslicarbazepine acetate is an S-licarbazepine acetate prodrug, which blocks the conduction of action potentials to inhibit the repeated abnormal discharge of brain neurons and control epileptic seizures

The original research eslicarbazepine acetate was jointly developed by Bial-Portela, Eisai, and Sumitomo Dainippon.

In China, the original eslicarbazepine acetate has not been approved for marketing, but the drug has been included in the "Second Batch of Encouraging Generic Drugs List" published on the National Health Commission website in March 2021

At present, a number of domestic companies have deployed the eslicarbazepine generic drug market

Epilepsy is one of the three major diseases of the human central nervous system.

According to data from Minai.

In addition to eslicarbazepine, three antiepileptic drugs, vigabatrin, brivaracetam and perampanel, have also been included in the list of encouraged generic drugs

Gamma-aminobutyric acid (GABA) is an analogue of γ-aminobutyric acid (GABA).

Buvaracetam, also known as brivaracetam, is similar in structure to levetiracetam.

The original research perampanel (Fycompa) is a highly selective and non-competitive AMPA-type glutamate receptor antagonist developed by Eisai.

In addition, China also approved the first imitation of lacosamide in 2019